irasia.com - Investor Relations Asia Pacific
HOME

Mesoblast Limited

Announcements / Press Releases


Please download the latest "Acrobat Reader" to view the PDF.

  • 2011-December-9
  • Form 604 Notice of Change of Interests of Sub Holder (in PDF)
  • 2011-November-24
  • Results of Meeting (in PDF)
  • 2011-November-24
  • Corporate Strategy Key to Mesoblast's Success (in PDF)
  • 2011-November-24
  • A Year of Transformation - Address by Mesoblast Chairman Mr Brian Jamieson - 2011 Annual General Meeting (in PDF)
  • 2011-November-22
  • Positive Outcome from FDA Meeting for Diabetes Program (in PDF)
  • 2011-November-15
  • Positive Heart Failure Trial Results Presented to AHA (in PDF)
  • 2011-November-10
  • Positive Results Using Adult Stem Cells for Type 2 Diabetes (in PDF)
  • 2011-October-31
  • Appendix 4C - Quarterly (in PDF)
  • 2011-October-28
  • Response to ASX Price Query Letter (in PDF)
  • 2011-October-24
  • Notice of Annual General Meeting/Proxy Form (in PDF)
  • 2011-October-24
  • Clearance for First Phase 2 Clinical Trial for Eye Diseases (in PDF)
  • 2011-October-20
  • Licensing Executives Society (U.S.A. and Canada) 2011 Deals of Distinction™ Award for Life Sciences to Mesoblast, Cephalon Alliance (in PDF)
  • 2011-September-27
  • MSB and Lonza Form Strategic Global Manufacturing Alliance (in PDF)
  • 2011-September-5
  • First European Trial for Heart Attack Treatment Cleared (in PDF)
  • 2011-August-31
  • Financial Report for the Year Ended 30 June 2011 (in PDF)
  • 2011-August-24
  • Mesoblast in Position of Considerable Strength (in PDF)
  • 2011-August-24
  • Appendix 4E - Preliminary Final Report Year Ending on 30 June 2011 (in PDF)
  • 2011-August-22
  • First Minimally Invasive Procedure for Lumbar Disc Repair (in PDF)
  • 2011-August-21
  • Mesoblast Limited Results Briefing (in PDF)
  • 2011-August-15
  • Heart Failure Trial Selected for AHA Special Session (in PDF)
  • 2011-August-1
  • Appendix 4C - Quarterly Report for Entities Admitted on the Basis of Commitments (in PDF)
  • 2011-July-7
  • FDA Clearance for Phase 3 Bone Marrow Transplant Trial (in PDF)
  • 2011-July-6
  • Appendix 3B (in PDF)
  • 2011-July-4
  • Amended Change of Director's Interest Notice - Michael Spooner (in PDF)
  • 2011-June-29
  • FDA Clears Phase 2 Trial to Treat Degenerative Disc Disease (in PDF)
  • 2011-June-14
  • Key Product Franchises Featured at Nomura Asia Equity Forum (in PDF)
  • 2011-June-9
  • Phase 2 Clinical Trial Results Show that Revascor™ Increases Blood Supply to Damaged Heart Muscle (in PDF)
  • 2011-June-6
  • MSB to Present at Goldman Sachs Global Healthcare Conference (in PDF)
  • 2011-May-24
  • Key USA Patents Increase Commercial Rights and Indications (in PDF)
  • 2011-May-2
  • Appendix 4C - Quarterly Report for Entities Admitted on the Basis of Commitments (in PDF)
  • 2011-April-18
  • Mesoblast Included in S&P/ASX 200 Index (in PDF)
  • 2011-April-11
  • Appendix 3B (in PDF)
  • 2011-April-7
  • Mesoblast Update on Valeant Proposal to Cephalon (in PDF)
  • 2011-March-31
  • Mesoblast Statement on Valeant Proposal to Cephalon (in PDF)
  • 2011-March-17
  • Mesoblast CEO Named BioSpectrum Asia Person of the Year 2011 (in PDF)
  • 2011-March-11
  • Appendix 3B (in PDF)
  • 2011-February-28
  • Financial Report for the Half-Year Ended 31 December 2010 (in PDF)
  • 2011-February-28
  • Mesoblast Half-Year Results, Strong Financial Position Underpins Company's Ability to Deliver in Increased Value from Broadened Range of Stem Cell Therapeutics (in PDF)
  • 2011-February-28
  • Appendix 4D - Half Year Report for the Six Months to 31 December 2010 (in PDF)
  • 2011-February-14
  • Cleansing Notice under Section 708A (in PDF)
  • 2011-February-14
  • Mesoblast Issues New Equity to Cephalon, Receives Further Cash Injection (in PDF)
  • 2011-February-11
  • Appendix 3B - New Issue Announcement, Application for Quotation of Additional Securities and Agreement (in PDF)
  • 2011-February-11
  • Section 708AA Notice - Cleansing Statement (in PDF)
  • 2011-February-9
  • Results of Extraordinary General Meeting (in PDF)
  • 2011-February-9
  • Address by Mesoblast Chairman Brian Jamieson at Extraordinary General Meeting (in PDF)
  • 2011-January-31
  • Mesoblast Reports Strong Cash Position after Angioblast Acquisition & Appendix 4C (in PDF)
  • 2011-January-12
  • Response to ASX Price Query (in PDF)
  • 2011-January-12
  • Mesoblast - Cephalon Alliance Highlighted at JP Morgan Healthcare Conference (in PDF)
  • 2011-January-10
  • Interim Results from Mesoblast's Phase 2 Heart Failure Trial Shows "Off-The- Shelf" Proprietary Adult Stem Cell Product Revascor™ Reduces Cardiac Events, Mortality, and Hospitalization (in PDF)
  • 2011-January-7
  • Notice of Extraordinary General Meeting/Proxy Form (in PDF)
  • 2017
  • 2017 Announcements / Press Releases
  • 2016
  • 2016 Announcements / Press Releases
  • 2015
  • 2015 Announcements / Press Releases
  • 2014
  • 2014 Announcements / Press Releases
  • 2013
  • 2013 Announcements / Press Releases
  • 2012
  • 2012 Announcements / Press Releases
  • 2010
  • 2010 Announcements / Press Releases
  • 2009
  • 2009 Announcements / Press Releases
  • 2008
  • 2008 Announcements / Press Releases
  • 2007
  • 2007 Announcements / Press Releases


  • Company's Index
  • irasia.com

  • About irasia.com   |   Terms of Use   |   Privacy Policy Statement   |   Disclaimer
    © Copyright 1996-2024 irasia.com Ltd. All rights reserved.
    DISCLAIMER:
    irasia.com Ltd. makes no guarantee as to the accuracy or completeness of any information provided on this website. Under no circumstances shall irasia.com Ltd. be liable for damages resulting from the use of the information provided on this website.